A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.
Metastatic Breast Cancer
DRUG: Utidelone and capecitabine
CNS-ORR（RANO Standard）, CNS-ORR（RANO Standard）, From the date of enrollment to the date of first documented progression or death from any cause, whichever comes first，assessed up to 48 months.
CNS-ORR (RECIST1.1 standard), CNS-ORR (RECIST1.1 standard), From the date of enrollment to the date of first documented progression or death from any cause, whichever comes first，assessed up to 48 months.|CNS-PFS assessed by the investigator, CNS-PFS assessed by the investigator, From the date of enrollment to the date of first documented progression or death from any cause, whichever comes first，assessed up to 48 months.
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.